Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched its updated t:slim X2 insulin pump software with the Dexcom (Nasdaq:DXCM) G7. Integration makes Tandem the first to offer automated insulin delivery with the latest-generation Dexcom continuous glucose monitor (CGM). The FDA cleared the next-generation Dexcom G7 in December 2022. By February of this year, the […]
Tandem Diabetes Care
Tandem stock sinks after hours on Q3 misses, lowered guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares took a massive hit after hours today on third-quarter results that missed the consensus forecast. Shares of TNDM fell nearly 20% at $14.27 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day up 1.1%. The […]
Tandem Diabetes Care has positive artificial pancreas data
Data from a Tandem Diabetes Care (Nasdaq:TNDM) study demonstrated the benefits of its automated insulin delivery technology. Diabetes Technology & Therapeutics made data available from the Control-IQ Observational (CLIO) study. It’s the largest prospective study of the Control-IQ advanced hybrid closed-loop technology to date. Twelve-month results showed, among other results, lower adverse events for type […]
Tandem Diabetes Care CCO is set to resign
Tandem Diabetes Care (Nasdaq:TNDM) filed an SEC Form 8-K announcing its chief commercial officer’s intent to resign. Brian B. Hansen, EVP and CCO, notified the company of his decision to resign on Aug. 17. His resignation goes into effect on Dec. 31, 2023. In connection with Hansen’s resignation, he and the automated insulin delivery technology […]
Tandem provides pathway to transition to new insulin pump platform
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it made a new, limited-time offer for its Tandem Choice technology access program. San Diego-based Tandem Diabetes Care’s program provides new and renewing, eligible users of its insulin pump a pathway to its new offerings. Users of the t:slim X2 insulin pump in the U.S. can use the […]
Tandem resets 2023 guidance due to reduced sales visibility from new product disruption
Tandem Diabetes Care (Nasdaq:TNDM) shares took a hit on second-quarter results that included amended full-year financial guidance. Changes to the automated insulin delivery technology maker’s outlook reflect updates to its portfolio and reduced visibility on sales for the near future. Shares of TNDM fell 15% to $27.19 apiece after the market closed today. MassDevice’s MedTech 100 […]
8 drug delivery innovations you should know
Innovations in drug delivery never stop, and over the past 12 months or so a wide variety have been in the spotlight. Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing the many ways we can […]
FDA clears Tandem Diabetes Care’s Mobi durable automated insulin pump
Tandem Diabetes Care (Nasdaq:TNDM) announced today that the FDA cleared its Tandem Mobi automated insulin delivery (AID) system. Clearance covers people with diabetes ages six and up, expanding the Tandem portfolio of products. San Diego-based Tandem says Mobi, which is fully controllable from a mobile app, is the world’s smallest durable AID system. Mobi features […]
Tandem stock dips after hours on Q1 misses as it teases 2023 product launches
Tandem Diabetes Care (Nasdaq:TNDM) shares ticked down after hours today on first-quarter results that fell shy of the consensus forecast. Shares of TNDM fell 9.9% to $36 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.3%. The […]
Tandem reports positive research for its artificial pancreas tech
Tandem Diabetes Care (Nasdaq:TNDM) today announced a positive meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology. The research found immediate and sustained improvements for a diverse range of subjects using Control-IQ technology, according to the research published in the journal Diabetes Technology & Therapeutics. There was an average increase in […]